title: Epoetin alfa in cancer patients: evidence-based guidelines.
abstract: Anemia is a common cause of cancer-related fatigue. A systematic review of the literature was performed to establish guidelines on the use of epoetin alfa for the treatment of anemia. The evidence in support of these guidelines was selected, reviewed, and summarized by the members of the Canadian Cancer and Anemia Guidelines Development Group. The effects of epoetin alfa on quality of life (QOL) in patients with cancer were examined in 5 randomized, placebo-controlled trials and 2 large, open-label, nonrandomized, community-based studies. The effects of epoetin alfa on red blood cell transfusion requirements were examined in 19 randomized controlled trials (RCTs) with 21 comparisons. All trials compared epoetin alfa to a suitable control group, examined specified outcome measures that could be analyzed, and studied patients with cancer who were receiving chemotherapy. Trials involving patients with hematologic malignancies originating in the bone marrow were excluded. Outcome measures included 1) quality of life (QOL) (as measured by scales including the Linear Analogue Self-Assessment [LASA] and the Functional Assessment of Cancer Therapy [FACT] subscales), and 2) transfusion requirements (as measured by the proportion of patients requiring transfusion and amount of transfusion). The analysis confirmed that epoetin alfa produced statistically significant and clinically relevant improvements in QOL in patients with cancer. The overall relative risk ratio for transfusion among patients receiving epoetin alfa was calculated to be 0.60 (95% Cl, 0.53-0.69; P < 0.00001), representing a 40% reduction in the proportion of patients requiring transfusion. These results support recommendations for the use of epoetin alfa in patients with cancer-related anemia.
authors.affiliation: Division of Clinical Hematology, Cross Cancer Institute, University of Alberta Hospital, 11560 University Avenue NW, Edmonton, Alberta T6G 1Z2, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Turner
authors.forename: P
authors.initials: P
authors.lastname: Anglin
authors.forename: R
authors.initials: R
authors.lastname: Burkes
authors.forename: F
authors.initials: F
authors.lastname: Couture
authors.forename: W
authors.initials: W
authors.lastname: Evans
authors.forename: G
authors.initials: G
authors.lastname: Goss
authors.forename: R
authors.initials: R
authors.lastname: Grimshaw
authors.forename: B
authors.initials: B
authors.lastname: Melosky
authors.forename: A
authors.initials: A
authors.lastname: Paterson
authors.forename: I
authors.initials: I
authors.lastname: Quirt
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000592:standards* / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa